IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
IPCA Laboratories reported strong FY2026 results with standalone revenue from operations of Rs. 7,336.75 crore, up 9.9% YoY from Rs. 6,677.92 crore. Consolidated revenue grew 7.9% to Rs. 9,646.33 crore. Standalone PAT surged 74% to Rs. 1,132.52 crore (vs Rs. 650.76 crore prior year), while consolidated PAT for owners rose 54.7% to Rs. 1,141.12 crore. Standalone EBITDA margin expanded by over 8 percentage points. Exceptional items totalled Rs. 281.54 crore (standalone) comprising impairment of subsidiary/associate exposures (Rs. 173 crore + Rs. 108.54 crore) and impact of new Labour Codes (Rs. 30.42 crore). The Board recommended dividend of Rs. 6 per share (600%) and re-appointed Mr. Prashant Godha as Executive Director for 5 years. Auditors issued unmodified (clean) opinion on both standalone and consolidated results. The company completed acquisition of Unichem Laboratories Limited (Ireland) during the year.
The company delivered exceptional profit growth and margin expansion despite a large exceptional items charge. Clean audit opinion and dividend payout signal financial health, though impairment charges and labour cost impact warrant monitoring of underlying operational performance.